Letters to the Editor

Guideline for management of non-Down syndrome neonates with a myeloproliferative disease on behalf of the I-BFM AML Study Group and EWOG-MDS

Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands; Department of Pediatric Oncology, Erasmus MC, Rotterdam, the Netherlands; Oncode Institute, Utrecht
Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands; Department of Pediatric Oncology, Erasmus MC, Rotterdam
Department of Pediatrics, St. Luke’s international Hospital, Tokyo
Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands; Dutch Childhood Oncology Group (DCOG), Utrecht
Department of Pediatric Oncology, University of Duisburg-Essen, Essen
Sapienza, University of Rome Department of Pediatric Hematology-Oncology, IRCCS Bambino Gesù Children’s Hospital, Rome
Department of Pediatric Hematology-Oncology and Stem Cell Transplantation, Ghent University Hospital, Ghent
Children's Cancer Research Institute and St. Anna Kinderspital, Department of Pediatrics, Medical University of Vienna, Vienna
Department of Genetics, University Medical Center, Utrecht
Department of Pediatric Hematology and Oncology, 2nd Faculty of Medicine, Charles University and University Hospital Motol, Prague
Department of Pediatric Hematology and Oncology, Comenius University Children's Hospital, Bratislava
Childhood Cancer Center, Skåne University Hospital, Lund
Pediatric Hematology, Oncology and Hemostaseology, Hospital for Children and Adolescents, University Hospital of Frankfurt/Main, Goethe-University Frankfurt/Main, Frankfurt
Department of Pediatric Onco-Hematology, University Hospital Miguel Servet, Zaragoza
Department of Hemato-Oncology, Immunology and Transplantation, University Pediatric Hospital Reine Fabiola (ULB), Brussels
Department of Pediatric Oncology, University of Duisburg-Essen, Essen
Fred Hutchinson Cancer Research Center, Clinical Research Division, Seattle, WA
Department of Pathology, St. Jude Children’s Hospital, Memphis, TN
Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg
Department of Pediatrics, Aarhus University Hospital, Aarhus
Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands University of Utrecht, Utrecht
Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands; Dutch Childhood Oncology Group (DCOG), Utrecht
Haematologica Early view Dec 2, 2021 https://doi.org/10.3324/haematol.2021.279507